Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 01 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-2.81 Insider Own0.70% Shs Outstand11.45M Perf Week-1.41%
Market Cap176.72M Forward P/E- EPS next Y-0.83 Insider Trans6.98% Shs Float11.41M Perf Month-19.60%
Income-32.17M PEG- EPS next Q-0.36 Inst Own68.21% Short Float / Ratio2.73% / 12.21 Perf Quarter7.78%
Sales4.41M P/S40.07 EPS this Y-3.54% Inst Trans0.95% Short Interest0.31M Perf Half Y-14.41%
Book/sh9.23 P/B1.67 EPS next Y59.51% ROA-19.76% Target Price74.00 Perf Year-27.35%
Cash/sh2.93 P/C5.25 EPS next 5Y19.00% ROE-22.60% 52W Range13.48 - 23.77 Perf YTD-16.41%
Dividend- P/FCF- EPS past 5Y- ROI-30.36% 52W High-35.30% Beta0.54
Dividend %- Quick Ratio3.34 Sales past 5Y32.47% Gross Margin79.32% 52W Low14.09% ATR1.03
Employees13 Current Ratio3.34 Sales Q/Q84.04% Oper. Margin-508.21% RSI (14)46.12 Volatility6.34% 7.16%
OptionableYes Debt/Eq0.00 EPS Q/Q-23.72% Profit Margin-729.31% Rel Volume0.97 Prev Close14.84
ShortableYes LT Debt/Eq0.00 EarningsNov 07 BMO Payout- Avg Volume25.54K Price15.38
Recom2.00 SMA20-3.12% SMA50-4.10% SMA200-12.73% Volume24,682 Change3.64%
Date Action Analyst Rating Change Price Target Change
Sep-07-21Downgrade Wedbush Outperform → Neutral $22
Jun-29-21Initiated Aegis Capital Buy $60
Jan-19-21Reiterated H.C. Wainwright Buy $30 → $56
Jan-18-18Reiterated H.C. Wainwright Buy $38 → $49
Oct-17-17Resumed H.C. Wainwright Buy $38
Sep-05-17Upgrade Wedbush Neutral → Outperform $9 → $19
Jun-12-17Initiated H.C. Wainwright Buy $15
Nov-14-16Downgrade Wedbush Outperform → Neutral $17 → $14
Mar-11-16Reiterated Wedbush Outperform $6 → $3
Jul-23-15Downgrade Jefferies Buy → Hold
Nov-07-23 07:50AM
Oct-31-23 07:30AM
Sep-25-23 07:30AM
Sep-06-23 07:30AM
10:43PM Loading…
Aug-31-23 10:43PM
Aug-13-23 10:07AM
Aug-08-23 08:21AM
Jun-23-23 06:14PM
Jun-22-23 07:30AM
Jun-20-23 07:30AM
May-16-23 09:29AM
May-09-23 07:53AM
07:30AM Loading…
Apr-26-23 07:30AM
Mar-30-23 07:30AM
Mar-21-23 07:30AM
Mar-10-23 05:36AM
Mar-09-23 07:50AM
Mar-06-23 08:28AM
Feb-28-23 07:30AM
Jan-06-23 07:00PM
Jan-04-23 07:30AM
Dec-22-22 07:30AM
Dec-07-22 07:44AM
Nov-22-22 07:01AM
Nov-06-22 09:24AM
Nov-03-22 09:05AM
07:30AM Loading…
Sep-27-22 08:30AM
Sep-21-22 07:30AM
Sep-07-22 07:30AM
Sep-01-22 06:20AM
Aug-11-22 06:22AM
Aug-04-22 10:45AM
Jun-30-22 07:33AM
Jun-20-22 07:30AM
Jun-02-22 01:00AM
May-30-22 07:06AM
May-17-22 04:05PM
May-07-22 08:27AM
May-05-22 08:55AM
May-03-22 08:15AM
Apr-20-22 08:24AM
Mar-21-22 07:30AM
Mar-15-22 06:21AM
Mar-10-22 09:43AM
Mar-08-22 07:30AM
Mar-01-22 07:30AM
Feb-17-22 07:30AM
Jan-21-22 10:21AM
Dec-23-21 07:30AM
Dec-21-21 07:30AM
Dec-16-21 07:30AM
Nov-22-21 11:46AM
Nov-15-21 06:01AM
Nov-04-21 10:15AM
Oct-28-21 03:06PM
Oct-27-21 04:50AM
Oct-14-21 06:57AM
Oct-08-21 03:35AM
Sep-22-21 07:30AM
Sep-21-21 12:33PM
Sep-20-21 07:30AM
Sep-13-21 07:30AM
Sep-07-21 01:49PM
Aug-10-21 04:35PM
Aug-05-21 08:45AM
Jul-29-21 03:05PM
Jul-28-21 07:30AM
Jul-15-21 06:38AM
Jun-23-21 03:16PM
Jun-21-21 07:30AM
Jun-08-21 10:38AM
May-21-21 08:00AM
May-06-21 09:15AM
May-03-21 07:30AM
Apr-15-21 09:05AM
Apr-12-21 07:30AM
Apr-06-21 07:02PM
Apr-05-21 04:05PM
Mar-23-21 08:00AM
Mar-22-21 07:30AM
Mar-10-21 08:45AM
Mar-03-21 05:16AM
Mar-02-21 12:30PM
Feb-23-21 04:05PM
Jan-04-21 04:05PM
XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sitko BradleyChief Investment OfficerOct 03Buy13.892503,4725,600Oct 04 04:30 PM
Sitko BradleyChief Investment OfficerOct 02Buy14.251,50021,3755,350Oct 04 04:30 PM
Hughes OwenExec Chairman and Interim CEOOct 02Buy13.831,00013,8303,500Oct 04 04:30 PM
Hughes OwenExec Chairman and Interim CEOSep 26Buy14.432,49936,0612,500Sep 27 04:30 PM
Hughes OwenExec Chairman and Interim CEOSep 25Buy14.651151Sep 27 04:30 PM
Sitko BradleyChief Investment OfficerMay 31Buy17.131,50025,7003,500Jun 02 04:30 PM
Hughes OwenInterim CEOMay 24Buy23.791,03224,5512,000May 25 04:30 PM
Hughes OwenInterim CEOMay 23Buy23.4696822,706968May 25 04:30 PM
Sitko BradleyChief Investment OfficerMay 23Buy19.0085016,1503,850May 25 04:30 PM
Sitko BradleyChief Investment OfficerMay 19Buy19.501,00019,5003,000May 22 04:30 PM
Sitko BradleyChief Investment OfficerMay 16Buy23.2050011,6022,000May 17 05:20 PM
Sitko BradleyChief Investment OfficerMay 15Buy23.401,50035,1001,500May 16 04:13 PM
Sitko BradleyChief Investment OfficerMay 12Buy18.992,00037,9852,000May 16 04:13 PM
BVF PARTNERS L P/ILDirectorJan 06Buy21.983,24971,4191,789,844Jan 09 05:44 PM
BVF PARTNERS L P/ILDirectorJan 05Buy18.3919,000349,3191,788,168Jan 09 05:44 PM